報價延遲最少15分鐘:2026/06/06 03:00 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
270.1 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
4.42/9.04
|
|
企業價值
30.06B
|
| 資產負債 |
|
每股賬面淨值
45.88
|
| 現金流量 |
|
現金流量率
0.04
|
| 損益表 |
|
收益
5.34B
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton'styrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products. |
